Astrazeneca Pty Ltd v GlaxoSmithKline Australia Pty Ltd

The case between Astrazeneca Pty Ltd and GlaxoSmithKline Australia Pty Ltd was heard before the court, with the central issue being a dispute regarding intellectual property rights. Astrazeneca, the appellant, had brought an appeal against a decision that went in favor of GlaxoSmithKline, the respondent. The nature of the dispute revolved around the validity of a patent held by GlaxoSmithKline, specifically concerning a method for the treatment of certain conditions. Astrazeneca argued that the patent was invalid on several grounds, including lack of novelty and obviousness.

The court was required to decide whether the patent held by GlaxoSmithKline was valid and enforceable. This involved assessing the claims made by Astrazeneca, such as the contention that the method described in the patent was not novel, and whether it was obvious to someone skilled in the art at the relevant time. Additionally, the court had to consider the evidence presented by both parties regarding the state of the prior art and the inventive step claimed by GlaxoSmithKline.

The court found that the patent was valid and enforceable, dismissing Astrazeneca's arguments on all counts. The reasoning involved a thorough examination of the prior art and the technical field in question, leading the court to conclude that the method described in the patent met the criteria for patentability. The court held that the patent was neither lacking in novelty nor obvious, thus affirming the original decision in favor of GlaxoSmithKline. Consequently, the appeal was dismissed, and Astrazeneca was ordered to pay the respondent’s costs.